TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Buy” by Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been given an average rating of “Buy” by the seven analysts that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $10.90.

Separately, Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $4.90 on Friday. The firm’s 50 day moving average price is $4.63 and its 200-day moving average price is $5.10. The firm has a market cap of $244.36 million, a PE ratio of -4.15 and a beta of 0.49. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $5.88.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The business had revenue of $11.21 million for the quarter, compared to the consensus estimate of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. Equities research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC raised its stake in TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after purchasing an additional 265,618 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in TriSalus Life Sciences by 16.0% during the 2nd quarter. Bridgeway Capital Management LLC now owns 75,400 shares of the company’s stock worth $411,000 after buying an additional 10,400 shares during the period. Bank of America Corp DE raised its holdings in shares of TriSalus Life Sciences by 1.8% in the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock valued at $1,030,000 after purchasing an additional 3,374 shares during the last quarter. AWM Investment Company Inc. bought a new position in shares of TriSalus Life Sciences in the second quarter valued at $6,812,000. Finally, Nantahala Capital Management LLC bought a new position in TriSalus Life Sciences during the second quarter worth $10,900,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.